Dual HER/VEGF Receptor Targeting Inhibits <i>In Vivo</i> Ovarian Cancer Tumor Growth
Marc A. Becker(Mayo Clinic), Paul Haluska(Mayo Clinic in Arizona), James Krempski(University of North Carolina at Chapel Hill), S. John Weroha(Mayo Clinic), Sean C. Harrington(Mayo Clinic), Tai W. Wong(Bristol-Myers Squibb (United States)), Thahir Farzan(Mayo Clinic), Xiaonan Hou(Mayo Clinic in Arizona), Kimberly R. Kalli(Mayo Clinic)
Cited by 7
Related Papers
Interferon-Regulatory Factor 4 Is Essential for the Developmental Program of T Helper 9 Cells
|Immunity|2010|539
Hormone-receptor expression and ovarian cancer survival: an Ovarian Tumor Tissue Analysis consortium study
|The Lancet Oncology|2013|434
Dose-Response Association of CD8<sup>+</sup> Tumor-Infiltrating Lymphocytes and Survival Time in High-Grade Serous Ovarian Cancer
|JAMA Oncology|2017|409
Tumor-Infiltrating Programmed Death Receptor-1+ Dendritic Cells Mediate Immune Suppression in Ovarian Cancer
|The Journal of Immunology|2011|250
Multi-omic profiling reveals widespread dysregulation of innate immunity and hematopoiesis in COVID-19
|The Journal of Experimental Medicine|2021|232